NotesFAQContact Us
Collection
Advanced
Search Tips
Showing all 3 results Save | Export
Peer reviewed Peer reviewed
Direct linkDirect link
Proctor, Tanja; Zimmermann, Samuel; Seide, Svenja; Kieser, Meinhard – Research Synthesis Methods, 2022
During drug development, a biomarker is sometimes identified as separating a patient population into those with more and those with less benefit from evaluated treatments. Consequently, later studies might be targeted, while earlier ones are performed in mixed patient populations. This poses a challenge in evidence synthesis, especially if only…
Descriptors: Comparative Analysis, Meta Analysis, Patients, Medical Research
Peer reviewed Peer reviewed
Direct linkDirect link
Nejstgaard, Camilla Hansen; Lundh, Andreas; Abdi, Suhayb; Clayton, Gemma; Gelle, Mustafe Hassan Adan; Laursen, David Ruben Teindl; Olorisade, Babatunde Kazeem; Savovic, Jelena; Hróbjartsson, Asbjørn – Research Synthesis Methods, 2022
Randomised trials are often funded by commercial companies and methodological studies support a widely held suspicion that commercial funding may influence trial results and conclusions. However, these studies often have a risk of confounding and reporting bias. The risk of confounding is markedly reduced in meta-epidemiological studies that…
Descriptors: Medical Research, Randomized Controlled Trials, Corporations, Financial Support
Peer reviewed Peer reviewed
Direct linkDirect link
Freeman, Suzanne C.; Carpenter, James R. – Research Synthesis Methods, 2017
Network meta-analysis (NMA) combines direct and indirect evidence from trials to calculate and rank treatment estimates. While modelling approaches for continuous and binary outcomes are relatively well developed, less work has been done with time-to-event outcomes. Such outcomes are usually analysed using Cox proportional hazard (PH) models.…
Descriptors: Bayesian Statistics, Network Analysis, Meta Analysis, Data